First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset

Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta, Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta

Abstract

This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death-ligand 1 (PD-L1) tumor proportion score of 50% or greater evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-point was progression-free survival; secondary end-points included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). The hazard ratio (HR) for progression-free survival by independent central review (data cut-off date, 10 July 2017) was 0.25 (95% confidence interval [CI], 0.10-0.64; one-sided, nominal P = .001). The HR for overall survival (data cut-off date, 15 February 2019) was 0.39 (95% CI, 0.17-0.91; one-sided, nominal P = .012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and four patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score of 50% or greater. The trial is registered with ClinicalTrials.gov: NCT02142738.

Keywords: Japan; PD-L1 protein; non-small-cell lung carcinoma; pembrolizumab; treatment outcome.

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Figures

FIGURE 1
FIGURE 1
CONSORT flow diagram of recruitment of the Japan subset of patients with previously untreated metastatic non‐small‐cell lung cancer in the KEYNOTE‐024 study of pembrolizumab vs chemotherapy. aThe remaining patients did not meet study eligibility criteria (n = 14). bIncludes 10 patients who crossed over to pembrolizumab treatment during the study. cIncludes clinical progression. PD‐L1, programmed death‐ligand 1; TPS, tumor proportion score
FIGURE 2
FIGURE 2
Kaplan‐Meier estimates of (A) progression‐free survival (PFS) per RECIST version 1.1 per independent central review (data cut‐off date, 10 July 2017), (B) PFS per RECIST version 1.1 per investigator review (data cut‐off date, 15 February 2019), and (C) overall survival (OS) in the subset of patients with previously untreated metastatic non‐small‐cell lung cancer in the KEYNOTE‐024 study of pembrolizumab vs chemotherapy. CI, confidence interval; HR, hazard ratio; NR, not reached.
FIGURE 3
FIGURE 3
Duration of treatment and time to response among patients in the pembrolizumab arm of the KEYNOTE‐024 study with an objective response (ie, complete response or partial response [PR]) per RECIST version 1.1 by investigator review (data cut‐off, date 15 February 2019). Bar lengths indicate duration of treatment (first course, dark green; second course, medium green) and months of follow‐up (light green). Tumor response (ie, PR, stable disease [SD], and progressive disease [PD]) is expressed per RECIST version 1.1 by investigator review only. AE, adverse event; PD–L1, programmed death‐ligand 1; TPS, tumor proportion score

References

    1. Satouchi M, Nosaki K, Takahashi T, et al. First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset. Cancer Sci. 2020;111:4480‐4489. 10.1111/cas.14647
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394‐424.
    1. Editorial Board of Cancer Statistics in Japan . Cancer Statistics in Japan ‐ 2017. 2018. . Accessed August 26, 2020
    1. Japan Lung Cancer Society . Guidelines for lung cancer clinical practice 2018 edition: Non‐small cell lung cancer. 2018. Accessed January 11, 2019
    1. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence‐Based Care. First‐line systemic chemotherapy in the treatment of advanced non‐small cell lung cancer: a systematic review. J Thorac Oncol. 2010;5:260‐274.
    1. National Comprehensive Cancer Network (NCCN) . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non‐small cell lung cancer, version 5.2019. 2019. . Accessed June 12, 2019
    1. Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non‐small cell lung cancer: A meta‐analysis of randomized controlled trials. Medicine (Baltimore). 2018;97:e11936.
    1. Akamatsu H, Ninomiya K, Kenmotsu H, et al. The Japanese Lung Cancer Society guideline for non‐small cell lung cancer, stage IV. Int J Clin Oncol. 2019;24:731‐770.
    1. Peters S, Kerr KM, Stahel R. PD‐1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev. 2018;62:39‐49.
    1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small‐cell lung cancer. N Engl J Med. 2015;372:2018‐2028.
    1. Reck M, Rodriguez‐Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer. N Engl J Med. 2016;375:1823‐1833.
    1. Reck M, Rodriguez‐Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE‐024: pembrolizumab versus platinum‐based chemotherapy for advanced non‐small‐cell lung cancer with PD‐L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37:537‐546.
    1. Soo RA, Kawaguchi T, Loh M, et al. Differences in outcome and toxicity between Asian and Caucasian patients with lung cancer treated with systemic therapy. Future Oncol. 2012;8:451‐462.
    1. Soo RA, Loh M, Mok TS, et al. Ethnic differences in survival outcome in patients with advanced stage non‐small cell lung cancer: results of a meta‐analysis of randomized controlled trials. J Thorac Oncol. 2011;6:1030‐1038.
    1. Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD‐L1 immunohistochemistry assay for pembrolizumab therapy in non‐small‐cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24:392‐397.
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell lung cancer (KEYNOTE‐010): a randomised controlled trial. Lancet. 2016;387:1540‐1550.
    1. Fukuoka M, Yano S, Giaccone G, et al. Multi‐institutional randomized phase II trial of gefitinib for previously treated patients with advanced non‐small‐cell lung cancer (The IDEAL 1 Trial). [corrected] J Clin Oncol. 2003;21:2237‐2246.
    1. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): a randomised, open‐label, controlled, phase 3 trial. Lancet. 2019;393:1819‐1830.
    1. Merck’s KEYTRUDA® (pembrolizumab) receives five new approvals in Japan, including in advanced non‐small cell lung cancer, as adjuvant therapy for melanoma, and in advanced microsatellite instability‐high tumors. 2019. . Accessed July 15, 2021
    1. Gandhi L, Rodriguez‐Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med. 2018;378:2078‐2092.
    1. Paz‐Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non‐small‐cell lung cancer. N Engl J Med. 2018;379:2040‐2051.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다